Cargando…

Virtual screening of RAGE inhibitors using molecular docking

Advanced Glycation End products (AGEs) interaction with Receptor for AGEs (RAGE) activates downstream signaling and evokes inflammatory responses in vascular cells. Therefore, it is of interest to design a novel series of molecules with a library of 352 compounds based on natural Isoflavone and Argp...

Descripción completa

Detalles Bibliográficos
Autores principales: Devi Alaparthi, Malini, Gopinath, Gudipudi, Bandaru, Srinivas, Sankeshi, Venu, Mangalarapu, Madhavi, Sudha Nagamalla, Swetha, Sudhakar, Kota, Roja Rani, Anupalli, Rao Sagurthi, Someswar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267955/
https://www.ncbi.nlm.nih.gov/pubmed/28149046
http://dx.doi.org/10.6026/97320630012124
Descripción
Sumario:Advanced Glycation End products (AGEs) interaction with Receptor for AGEs (RAGE) activates downstream signaling and evokes inflammatory responses in vascular cells. Therefore, it is of interest to design a novel series of molecules with a library of 352 compounds based on natural Isoflavone and Argpyrimidine moities. The compounds screened against the optimized structure of RAGE (PDB code: 3CJJ) using MolDock aided with molecular docking algorithm. This exercise identified compound number 62 with appreciable ADME properties having no toxicity and pharmacophore features. Therefore, compound 62 identified as a RAGE inhibitor is proposed for further validation in the context of Diabetic Retinopathy (DR) and vascular complications.